Details of the Drug

General Information of Drug (ID: DML0RAE)

Drug Name
Methoxyflurane
Synonyms
Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Therapeutic Class
Anesthetics
Affected Organisms
Humans and other mammals
ATC Code
N02BG09: Methoxyflurane
N02BG: Other analgesics and antipyretics
N02B: OTHER ANALGESICS AND ANTIPYRETICS
N02: ANALGESICS
N: NERVOUS SYSTEM
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 164.96
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C3H4Cl2F2O
IUPAC Name
2,2-dichloro-1,1-difluoro-1-methoxyethane
Canonical SMILES
COC(C(Cl)Cl)(F)F
InChI
InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
InChIKey
RFKMCNOHBTXSMU-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4116
ChEBI ID
CHEMBL6843
CAS Number
76-38-0
UNII
30905R8O7B
DrugBank ID
DB01028
TTD ID
D07SOO
INTEDE ID
DR1048
Drug Pharmacogenomic Perturbation (DPP)NEW Click to Jump to the Detailed DPP Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
GABA(A) receptor alpha-1 (GABRA1) TT1MPAY GBRA1_HUMAN Antagonist [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [4]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [3]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [3]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Substrate [5]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [3]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methoxyflurane (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Decreased renal excretion of Methoxyflurane caused by Remdesivir mediated nephrotoxicity. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [6]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Methoxyflurane and Inotersen. Amyloidosis [5D00] [7]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Streptomycin. Bacterial infection [1A00-1C4Z] [7]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Etidronic acid. Bone paget disease [FB85] [8]
Phenobarbital DMXZOCG Moderate Increased metabolism of Methoxyflurane caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [9]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [7]
Rifampin DMA8J1G Moderate Increased metabolism of Methoxyflurane caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [7]
Givosiran DM5PFIJ Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [7]
Amobarbital DM0GQ8N Moderate Increased metabolism of Methoxyflurane caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [9]
Ceritinib DMB920Z Moderate Decreased metabolism of Methoxyflurane caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [6]
Moxetumomab pasudotox DMN63DZ Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Moxetumomab pasudotox. Mature B-cell leukaemia [2A82] [7]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Methoxyflurane and Exjade. Mineral absorption/transport disorder [5C64] [10]
Ibuprofen DM8VCBE Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Ibuprofen. Pain [MG30-MG3Z] [7]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Methoxyflurane and Everolimus. Renal cell carcinoma [2C90] [11]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Methoxyflurane and Temsirolimus. Renal cell carcinoma [2C90] [11]
Colistimethate DMZ9BMU Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Colistimethate. Respiratory infection [CA07-CA4Z] [7]
Telavancin DM58VQX Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [7]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Olsalazine. Ulcerative colitis [DD71] [12]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Methoxyflurane and Plazomicin. Urinary tract infection [GC08] [7]
⏷ Show the Full List of 19 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7234).
2 DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3 Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
4 Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
5 Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
6 Cerner Multum, Inc. "Australian Product Information.".
7 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8 Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
9 Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456]
10 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
11 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
12 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]